Research shows that CD27 activation boosts antitumor immune responses in HER2+ breast cancer, suggesting new vaccine approaches.
A recent study shows that CD27 agonism can improve the efficacy and durability of vaccine-induced antitumor responses in HER2+ breast cancer. The outcomes may pave the way for approaches to improve the efficacy and durability of tumor antigen vaccines.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: